Intellia Therapeutics reported further progress with two treatments that are now ensconced in Phase III of testing. Click ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) just released its latest quarterly results and things are looking bullish. Revenues of US$17m beat estimates by a substantial 39% margin. Unfortunately, ...

NTLA reports better-than-expected first-quarter 2025 results. The company provides updates on its pipeline candidates. Shares rise.

Q1 2025 Management View CEO John Leonard emphasized that Intellia has made significant progress early in 2025, achieving two key milestones: dosing the first patient in Phase 3 studies for hereditary ...

Analysts expect Intellia Therapeutics to report an earnings per share (EPS) of $-1.27. Anticipation surrounds Intellia ...

CRISPR Therapeutics and Intellia face 2025 volatility, but CRSP’s strong cash and launches make it more attractive than NTLA.

The popular growth investor keeps adding to some of her favorite stocks.

Intellia will present additional data from the ongoing Phase 1/2 study in an oral presentation at the European Academy of ...

Intellia Therapeutics NTLA incurred a loss of $1.10 per share (including one-time expenses of change in fair value of investments) in the first quarter of 2025, which was narrower than the Zacks ...